病程及其他特征对托珠单抗治疗类风湿关节炎临床试验疗效的影响
该汇总分析基于申办方开展的3期和4期临床试验,评估生物制剂初治的 established RA 患者中,病程单独或联合其他基线临床及非临床因素对托珠单抗起始治疗后结局差异的解释程度。结果显示,病程虽有统计学显著性,但仅解释 CDAI 和 HAQ-DI 评分变化<2%的变异,结论认为病程对托珠单抗疗效的影响统计学显著但临床意义很小。
要点
- 病程仅解释托珠单抗治疗24周 CDAI 和 HAQ-DI 变化<2%的变异。
- 基线 CDAI 和 HAQ-DI 值分别解释32%和15%的变异。
- 病程加倍仅降低 ACR50 应答 odds 9%,每增加5年降低 CDAI 缓解 odds 15%。
核心结论
- 在生物制剂初治的 established RA 患者中,病程单独或联合其他基线特征对托珠单抗起始治疗结局的影响统计学显著但临床意义很小。
研究设计与样本
- 申办方开展的3期和4期临床试验的汇总分析,评估生物制剂初治的 established RA 患者中托珠单抗起始治疗的应答预测因素。
主要发现
- 所有 investigated 结局在托珠单抗治疗患者中均观察到改善。
- 病程在模型中统计学显著,但仅解释 CDAI 和 HAQ-DI 评分从基线至第24周变化<2%的变异。
- 基线 CDAI 和 HAQ-DI 值分别解释32%和15%的变异。
- 病程加倍使达到 ACR50 应答的 odds 仅降低9%,每增加5年病程使达到 CDAI 缓解(≤2.8)的 odds 仅降低15%。
关键数值与推荐
- 应答以第24周 CDAI 和 HAQ-DI 评分较基线变化、ACR50 应答比例及 CDAI 缓解(≤2.8)率衡量。
- 病程加倍降低 ACR50 应答 odds 9%,每增加5年降低 CDAI 缓解 odds 15%。
临床怎么用
- 对于生物制剂初治的 established RA 患者,不应仅因病程较长而排除托珠单抗起始治疗,因其对疗效的影响临床意义很小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the extent to which disease duration, alone or in combination with other baseline clinical and non-clinical factors, explains variations in outcome of tocilizumab initiated in biologic-naïve patients with established RA. METHODS: In this pooled analysis of phase 3 and 4 clinical trials conducted by the sponsor, predictors of response, including demographics, disease characteristics at baseline (start of tocilizumab dosing) and study characteristics (e.g. patient inclusion criteria, tocilizumab dosing regimen) were evaluated. Response was measured as change from baseline to week 24 in Clinical Disease Activity Index (CDAI) and HAQ-Disability Index (HAQ-DI) scores and as the proportions of patients who experienced ≥50% improvement based on ACR criteria (ACR50) and CDAI remission (≤2.8) rates at week 24. RESULTS: Improvements in all outcomes investigated were observed in patients receiving tocilizumab. Although disease duration was statistically significant in the models, it accounted for <2% of variation in CDAI and HAQ-DI score changes from baseline to week 24; baseline CDAI and HAQ-DI values accounted for 32% and 15% of variations, respectively. Doubling of disease duration reduced the odds of achieving an ACR50 response by only 9%, and each additional 5-year period of disease duration decreased the odds of achieving CDAI remission by only 15%. CONCLUSION: RA duration, alone or in combination with other baseline characteristics, had a statistically significant but clinically small effect on the outcomes of tocilizumab initiated in biologic-naïve patients with established RA.
引用
- Rubbert-Roth A, Aletaha D, Devenport J, et al. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 32844216. doi:10.1093/rheumatology/keaa259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。